Drugs / TPM502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05660109 | Dec 2022 → Jul 2024 | celiac disease | Topas Therapeutics GmbH | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-05-06 | Topas Therapeutics GmbH | Results Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients topas-therapeutics.com ↗
Data from a Phase 2a clinical trial evaluating TPM502, the company’s lead candidate, demonstrated a positive safety and tolerability profile, a significant reduction of the inflammatory responses to gluten and long-lasting phenotypic changes to gliadin-specific T cells. |
| 2024-10-15 | Topas Therapeutics GmbH | Results Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease topas-therapeutics.com ↗
Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with celiac disease. |
| 2023-05-25 | Topas Therapeutics GmbH | Regulatory Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease topas-therapeutics.com ↗
The company has received approval to initiate TPM502’s clinical development in a Phase 2a study based on TPM502 preclinical data and clinical results from the Phase 1 study assessing Topas’ TPC TPM203 in patients with pemphigus vulgaris. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-06 | Topas Therapeutics GmbH | Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients topas-therapeutics.com ↗ |
| 2025-04-24 | Topas Therapeutics GmbH | Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego topas-therapeutics.com ↗ |
| 2024-10-15 | Topas Therapeutics GmbH | Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease topas-therapeutics.com ↗ |
| 2023-05-25 | Topas Therapeutics GmbH | Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease topas-therapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPM502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05660109 ↗ |
| Modality | Peptide | “TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5” NCT05660109 ↗ |